FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367677780> ?p ?o ?g. }

• W4367677780 abstract "Purpose Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up. Methods and Materials After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancillary project was disease progression (composite of biochemical failure, local failure, distant metastasis, prostate cancer-specific mortality, and use of salvage therapy). Individual endpoints were also assessed. Fine-Gray or cause-specific Cox multivariable models were constructed adjusting for randomization arm and trial stratification factors. Results Two-hundred fifteen patient samples passed quality control for analysis. The median follow-up was 12.8 years (range, 2.4-17.7). On multivariable analysis, the 22-gene GC (per 0.1 unit) was independently prognostic for disease progression (subdistribution hazard ratio [sHR], 1.12; 95% confidence interval [CI], 1.00-1.26; P = .04), biochemical failure (sHR, 1.22; 95% CI, 1.10-1.37; P < .001), distant metastasis (sHR, 1.28; 95% CI, 1.06-1.55; P = .01), and prostate cancer-specific mortality (sHR, 1.45; 95% CI, 1.20-1.76; P < .001). Ten-year distant metastasis in GC low-risk patients was 4% compared with 16% for GC high-risk patients. In patients with lower GC scores, the 10-year difference in metastasis-free survival rate between arms was –7%, compared with 21% for higher GC patients (P-interaction = .04). Conclusions This study represents the first validation of a biopsy-based gene expression classifier, assessing both its prognostic and predictive value, using data from a randomized phase 3 trial of intermediate-risk prostate cancer. Decipher improves risk stratification and can aid in treatment decision-making in men with intermediate-risk disease. Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up. After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancillary project was disease progression (composite of biochemical failure, local failure, distant metastasis, prostate cancer-specific mortality, and use of salvage therapy). Individual endpoints were also assessed. Fine-Gray or cause-specific Cox multivariable models were constructed adjusting for randomization arm and trial stratification factors. Two-hundred fifteen patient samples passed quality control for analysis. The median follow-up was 12.8 years (range, 2.4-17.7). On multivariable analysis, the 22-gene GC (per 0.1 unit) was independently prognostic for disease progression (subdistribution hazard ratio [sHR], 1.12; 95% confidence interval [CI], 1.00-1.26; P = .04), biochemical failure (sHR, 1.22; 95% CI, 1.10-1.37; P < .001), distant metastasis (sHR, 1.28; 95% CI, 1.06-1.55; P = .01), and prostate cancer-specific mortality (sHR, 1.45; 95% CI, 1.20-1.76; P < .001). Ten-year distant metastasis in GC low-risk patients was 4% compared with 16% for GC high-risk patients. In patients with lower GC scores, the 10-year difference in metastasis-free survival rate between arms was –7%, compared with 21% for higher GC patients (P-interaction = .04). This study represents the first validation of a biopsy-based gene expression classifier, assessing both its prognostic and predictive value, using data from a randomized phase 3 trial of intermediate-risk prostate cancer. Decipher improves risk stratification and can aid in treatment decision-making in men with intermediate-risk disease." @default.
• W4367677780 created "2023-05-03" @default.
• W4367677780 creator A5006174923 @default.
• W4367677780 creator A5012137565 @default.
• W4367677780 creator A5014582211 @default.
• W4367677780 creator A5017592031 @default.
• W4367677780 creator A5020006331 @default.
• W4367677780 creator A5024166434 @default.
• W4367677780 creator A5024741202 @default.
• W4367677780 creator A5037727718 @default.
• W4367677780 creator A5038004505 @default.
• W4367677780 creator A5038171309 @default.
• W4367677780 creator A5038819739 @default.
• W4367677780 creator A5039156745 @default.
• W4367677780 creator A5045162411 @default.
• W4367677780 creator A5048513152 @default.
• W4367677780 creator A5052233371 @default.
• W4367677780 creator A5055219686 @default.
• W4367677780 creator A5070623757 @default.
• W4367677780 creator A5076238068 @default.
• W4367677780 creator A5082271881 @default.
• W4367677780 creator A5084674472 @default.
• W4367677780 creator A5087189944 @default.
• W4367677780 date "2023-05-01" @default.
• W4367677780 modified "2023-10-09" @default.
• W4367677780 title "Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial" @default.
• W4367677780 cites W1508662657 @default.
• W4367677780 cites W2022785557 @default.
• W4367677780 cites W2108864389 @default.
• W4367677780 cites W2113499049 @default.
• W4367677780 cites W2582799849 @default.
• W4367677780 cites W2769578203 @default.
• W4367677780 cites W2791655860 @default.
• W4367677780 cites W2889201576 @default.
• W4367677780 cites W2897283235 @default.
• W4367677780 cites W3086866597 @default.
• W4367677780 cites W3113153998 @default.
• W4367677780 cites W3128740038 @default.
• W4367677780 cites W3204356979 @default.
• W4367677780 cites W4205879532 @default.
• W4367677780 cites W4281960705 @default.
• W4367677780 cites W4313398715 @default.
• W4367677780 cites W4367173078 @default.
• W4367677780 doi "https://doi.org/10.1016/j.ijrobp.2023.04.010" @default.
• W4367677780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37137444" @default.
• W4367677780 hasPublicationYear "2023" @default.
• W4367677780 type Work @default.
• W4367677780 citedByCount "0" @default.
• W4367677780 crossrefType "journal-article" @default.
• W4367677780 hasAuthorship W4367677780A5006174923 @default.
• W4367677780 hasAuthorship W4367677780A5012137565 @default.
• W4367677780 hasAuthorship W4367677780A5014582211 @default.
• W4367677780 hasAuthorship W4367677780A5017592031 @default.
• W4367677780 hasAuthorship W4367677780A5020006331 @default.
• W4367677780 hasAuthorship W4367677780A5024166434 @default.
• W4367677780 hasAuthorship W4367677780A5024741202 @default.
• W4367677780 hasAuthorship W4367677780A5037727718 @default.
• W4367677780 hasAuthorship W4367677780A5038004505 @default.
• W4367677780 hasAuthorship W4367677780A5038171309 @default.
• W4367677780 hasAuthorship W4367677780A5038819739 @default.
• W4367677780 hasAuthorship W4367677780A5039156745 @default.
• W4367677780 hasAuthorship W4367677780A5045162411 @default.
• W4367677780 hasAuthorship W4367677780A5048513152 @default.
• W4367677780 hasAuthorship W4367677780A5052233371 @default.
• W4367677780 hasAuthorship W4367677780A5055219686 @default.
• W4367677780 hasAuthorship W4367677780A5070623757 @default.
• W4367677780 hasAuthorship W4367677780A5076238068 @default.
• W4367677780 hasAuthorship W4367677780A5082271881 @default.
• W4367677780 hasAuthorship W4367677780A5084674472 @default.
• W4367677780 hasAuthorship W4367677780A5087189944 @default.
• W4367677780 hasConcept C121608353 @default.
• W4367677780 hasConcept C126322002 @default.
• W4367677780 hasConcept C143998085 @default.
• W4367677780 hasConcept C168563851 @default.
• W4367677780 hasConcept C203092338 @default.
• W4367677780 hasConcept C204243189 @default.
• W4367677780 hasConcept C207103383 @default.
• W4367677780 hasConcept C2776235491 @default.
• W4367677780 hasConcept C2777899217 @default.
• W4367677780 hasConcept C2780192828 @default.
• W4367677780 hasConcept C44249647 @default.
• W4367677780 hasConcept C50382708 @default.
• W4367677780 hasConcept C71924100 @default.
• W4367677780 hasConceptScore W4367677780C121608353 @default.
• W4367677780 hasConceptScore W4367677780C126322002 @default.
• W4367677780 hasConceptScore W4367677780C143998085 @default.
• W4367677780 hasConceptScore W4367677780C168563851 @default.
• W4367677780 hasConceptScore W4367677780C203092338 @default.
• W4367677780 hasConceptScore W4367677780C204243189 @default.
• W4367677780 hasConceptScore W4367677780C207103383 @default.
• W4367677780 hasConceptScore W4367677780C2776235491 @default.
• W4367677780 hasConceptScore W4367677780C2777899217 @default.
• W4367677780 hasConceptScore W4367677780C2780192828 @default.
• W4367677780 hasConceptScore W4367677780C44249647 @default.
• W4367677780 hasConceptScore W4367677780C50382708 @default.
• W4367677780 hasConceptScore W4367677780C71924100 @default.
• W4367677780 hasLocation W43676777801 @default.
• W4367677780 hasLocation W43676777802 @default.
• W4367677780 hasOpenAccess W4367677780 @default.
• W4367677780 hasPrimaryLocation W43676777801 @default.

• next